EUVIMEDEUVIMED entdecken
EditorialOpen Access

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?

Yao-Chun Hsu iD, Ming-Lung Yu iD

Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (3) · 404-405

DOI: 10.1111/apt.70734 ↗

Kurz gefasst

Editorial in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 15.05.2026. Verfasst von Yao-Chun Hsu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Research, E-Da Hospital, Kaohsiung, Taiwan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Medical Research, E-Da Hospital, Kaohsiung, Taiwan.
  • School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
  • Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • School of Medicine and Hepatitis Research Center, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.

ORCID-Profile: Yao-Chun Hsu, Ming-Lung Yu

Zitieren

APA

Hsu, Y. C., & Yu, M. L. (2026). Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?. Alimentary Pharmacology & Therapeutics, 64(3), 404-405. https://doi.org/10.1111/apt.70734

Vancouver

Hsu YC, Yu ML. Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?. Alimentary Pharmacology & Therapeutics. 2026;64(3):404-405. doi:10.1111/apt.70734

BibTeX
@article{Hsu2026,
  author = {Hsu, Yao-Chun and Yu, Ming-Lung},
  title = {Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {3},
  pages = {404--405},
  doi = {10.1111/apt.70734}
}
Kostenlos starten →